Insider Transactions in Q1 2024 at Kiniksa Pharmaceuticals, Ltd. (KNSA)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 07
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
65,012
-100.0%
|
$1,365,252
$21.02 P/Share
|
|
Mar 06
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
5,582
-7.91%
|
$117,222
$21.0 P/Share
|
|
Mar 04
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
12,742
-7.9%
|
$267,582
$21.66 P/Share
|
|
Mar 01
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
1,189
-0.96%
|
$26,158
$22.03 P/Share
|
|
Mar 01
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
656
+0.53%
|
$656
$1.59 P/Share
|
|
Mar 01
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
18,844
-29.57%
|
$395,724
$21.77 P/Share
|
|
Mar 01
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,844
+23.1%
|
$18,844
$1.86 P/Share
|
|
Mar 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
9,659
-35.45%
|
$202,839
$21.45 P/Share
|
|
Mar 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,659
+16.19%
|
$106,249
$11.36 P/Share
|
|
Feb 28
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
5,126
-22.57%
|
$107,646
$21.79 P/Share
|
|
Feb 28
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,126
+18.41%
|
$41,008
$8.83 P/Share
|
|
Feb 27
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,156
-18.45%
|
$213,276
$21.03 P/Share
|
|
Feb 27
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,156
+15.58%
|
$10,156
$1.86 P/Share
|
|
Jan 15
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
583
+3.21%
|
$6,996
$12.35 P/Share
|
|
Jan 03
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,000
-43.43%
|
$240,000
$20.0 P/Share
|
|
Jan 03
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+30.28%
|
$96,000
$8.83 P/Share
|
|
Jan 02
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
16,670
-49.5%
|
$316,730
$19.17 P/Share
|
|
Jan 02
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+33.11%
|
$216,710
$13.88 P/Share
|